

General Information

Venue and Travel

Novartis in Basel is easily accessible from the airport and railway station - just 15 minutes from both locations by taxi, tram or bus. The site is also easily accessible from nearby motorways.

Accommodation and Conference Dinner

Rooms will be held at discounted rates at a series of hotels close to the conference venue; and an optional conference dinner will be available on registration.

Registration

Registration is open, and some student bursaries are available.

Registration fees up to 22 Jan

£335 RSC/SCI member early

£395 Non-member early

£95 RSC/SCI student* member early

£130 Student* non-member early

* Student is undergraduate or post-graduate student, not post-doc

£40 Late fee for payments received from 13 March

£80 Conference dinner

Exhibition stands

£500 Exhibition stand including one full delegate fee

£575 Exhibition stand inc. two stand staff with no access to technical programme

Registration fees from 23 Jan to 12 Mar

£395 RSC/SCI member standard

£465 Non-member standard

£110 RSC/SCI student* member standard

£155 Student* non-member standard

Exhibition Opportunities

Those companies wishing to have a trade stand should apply early to avoid disappointment as these are limited.

Sponsors



Special thanks to Novartis for hosting this event. Additional sponsors would be welcomed.

Secretariat Contact

RSC-BMCS secretariat:

Maggi Churchouse, 3 East Barn, Market Weston Road, Theltham, Diss IP22 1JJ, UK

maggi@maggichurchouseevents.co.uk, telephone +44 (0)1359 221004

Websites

www.maggichurchouseevents.co.uk/bmcs

Also www.rsc.org/bmcs and www.soci.org/events

Organising Committee

Helena Danielson (Uppsala University)

Stephen East (Evotec)


Karl Gibson (Sandexis)

Fionna Martin (Lilly)

Richard Sedrani (Novartis)

Steve Swallow (chair) (AstraZeneca)

Second Announcement and Call for Posters



Proteinase 2015

9th RSC / SCI symposium on
proteinase inhibitor design

Monday-Tuesday, 13th-14th April 2015

Novartis, Basel, Switzerland

Call for Posters

Please see details overleaf



Introduction and Programme

Introduction

This symposium will cover progress in the design and synthesis of protease inhibitors for a diverse range of disease indications, while also covering a range of novel drug discovery activities: from 'Molecules to Medicines'.

Who should attend

This meeting is aimed at medicinal chemists and other scientists interested in furthering their knowledge of proteases in the context of drug discovery.

Programme

Monday, 13th April

- 09.00 Plenary: From weak fragments to highly potent and selective plasma kallikrein inhibitors
Stefanie Flohr, Novartis
- 10.00 Inhibitors of cathepsin C - not your typical oral small molecules
Michael Palovich, GlaxoSmithKline
- 10.45 Refreshments, exhibition and posters
- 11.15 Freezing the bioactive conformation – discovery of BAY 85-8501, a potent binder of human neutrophil elastase
Franz von Nussbaum, Bayer Pharma
- 12.00 Gamma secretase inhibitors: from Alzheimer's disease to a potential cancer treatment
Alexander Flohr, Roche
- 12.45 Lunch, exhibition and posters
- 13.45 Discovery of potent brain penetrant BACE inhibitors
Fionna Martin, Lilly
- 14.30 Discovery of MK-8931: a BACE inhibitor in phase 3 clinical development for Alzheimer's disease
Jared Cumming, Merck
- 15.15 Flash poster presentations
- 15.45 Refreshments, poster session and exhibition
- 16.30 Factor XIa inhibitors as new anticoagulants
Mimi Quan, BMS
- 17.15 Close

Programme cont.

Tuesday, 14th April

- 08.45 Plenary: Understanding the role of proteolysis in disease
Charles Craik (University of California, San Francisco)
- 09.45 Allosteric inhibitors of MALT1 paracaspase in targeted therapies
Daniel Krappmann, Helmholtz Zentrum München
- 10.30 Refreshments, exhibition and posters
- 11.15 Moving in the cathepsin target space - discovery of RG7236 as a potent and highly selective cathepsin S inhibitor
Wolfgang Haap, Roche
- 12.00 Drugging DUBs with an NMR pyramid
Gregg Siegal, ZoBio
- 12.45 Lunch, exhibition and posters
- 13.45 Discovery and structure-based optimization of adenain inhibitors
Eva Altmann, Novartis
- 14.30 Discovery of the macrocyclic HCV NS3/4A protease inhibitor MK-5172
Mike Rowley, Merck
- 15.15 Speaker to be confirmed
- 16.00 Closing remarks
- 16.05 Close

Call for Posters

The abstract submission deadline is 23rd February, and a template is available on the event website. Selected student speakers will be invited to deliver single-slide, two-minute flash presentations prior to the poster session.

